AUTHORS
Adolfo Aleman, PhD, Nikhit Kethidi, MD2, Saumya Pothukuchi3, Christina Kuhn, PhD4, Daniel Charytonowicz5, Zachary M. Avigan, MD, MHS6, Akankshaanil Anil Acharya7, Michael Tankelevich8, Jha Diva, PhD9, Matthias Ceulemans, PhD10, Shriya Desai11, Sidorela Reci12, Kedwin Ventura13, Rudra Prasad Dutta, PhD14, Meenakshi Mehrotra, PhD15, Rachel Brody, MD, PhD16, Seunghee Kim-Schulze, PhD17, Jane Houldsworth, PhD18, Maximilian Merz, MD19, Shambavi Richard, MD20, Sundar Jagannath, M.D.21, Alexandros Polydorides, MD22, Mayte SuarezFarinas23, Saurabh Mehandru, MD24, Samir Parekh, MD25
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 Icahn School of Medicine at Mount Sinai, New York, New York, United States
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Icahn School of Medicine at Mount Sinai, New York, New York, United States
17 Icahn School of Medicine at Mount Sinai, New York, New York, United States
18 Icahn School of Medicine at Mount Sinai, New York, New York, United States
19 Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany, Memorial Sloan Kettering Cancer Center, New York, United States
20 Icahn School of Medicine at Mount Sinai, New York, New York, United States
21 Icahn School of Medicine at Mount Sinai, New York, New York, United States
22 Icahn School of Medicine at Mount Sinai, New York, New York, United States
23 Icahn School of Medicine at Mount Sinai, New York, New York, United States
24 Icahn School of Medicine at Mount Sinai, New York, New York, United States
25 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Introduction
Anti-BMCA chimeric antigen receptor (CAR) T-cell therapies have transformed outcomes in multiple myeloma with durable responses. CAR-T cell-associated enterocolitis (CAR-TEC) has emerged as a delayed toxicity associated with anti-BCMA CAR-T cell therapy, with variable incidence, reaching as high as 6% in patients. This syndrome is associated with substantial morbidity, frequent corticosteroid dependence, resistance to conventional immunosuppressive therapies, and, in severe cases, mortality. Despite the growing prevalence of CAR-TEC remains poorly understood, and current management strategies are largely empiric. Here, we perform a comprehensive multimodal analysis of CAR-TEC with healthy individuals and asymptomatic CAR-T patient controls (CAR-TCTRL). We present a data driven approach to treating this serious secondary malignancy by targeting the interferon inflammatory pathway upregulated in our enterocolitis cases.
Methods
We compared intestinal biopsies of the small intestine and colon from 11 normal volunteers, 7 asymptomatic BCMA CAR-T–treated controls (CAR-TCTRL), and 10 multiple myeloma patients with CAR-T–associated enterocolitis (CAR-TEC). We implemented anti-Camelid staining of intestinal tissue to identify CAR-T presence in pathology tissue. We analyzed single-cell RNA sequencing data from the biopsies as well as peripheral blood (PB) using a custom reference genome incorporating the cilta-cel CAR construct to identify and transcriptionally profile CAR-T cells. Immune and stromal compartments of biopsies were further characterized by multiparameter flow cytometry, immunohistochemistry, immunofluorescence, systemic IgA, soluble BCMA (sBCMA), and fecal calprotectin. Longitudinal CAR-T expansion was quantified in all patients for identification of persistence in all groups.
Results
Anti-BCMA CAR-T therapy resulted in a profound mucosal plasma-cell and B-cell depletion in all patients suggesting that deep humoral depletion is a shared consequence of therapy but is not sufficient alone to cause enterocolitis. Both CAR-TEC and CAR-TCTRL patients exhibited an absence of IgA2 plasma cells in the intestines however CAR-TCTRL retained homeostatic transcriptional programs, while CAR-TEC displayed an expansion of highly cytotoxic and TH17-skewed T cells. We identified through scRNA that persistent BCMA CAR-T cells in the gut were cytotoxic and NK-like. Longitudinal tracking of PB CAR-T patients showed that CAR-TEC with persistent CAR-T proliferation had increased presence of gut homing receptors such as integrin beta 7 on CAR-T cells. CAR-TEC patients also displayed an interferon-inducible, JAK-STAT-enriched, trafficking-competent phenotype, in contrast to low-level, transient mucosal CAR-T detection in most CAR-TCTRL. In addition to CAR-T changes we observed myeloid, stromal, endothelial, epithelial, and glial remodeling in CAR-TEC patients. Immune cell populations converged on interferon- and NF-kB-driven activation, loss of homeostatic signaling, with ligand-receptor networks including MIF-CD74-CXCR4 and gut-homing endothelial programs that may recruit and retain cytotoxic the CAR-T cells. We found that we could use the diagnostic criteria of persistent loss of IgA and sBCMA together with elevated fecal calprotectin defined a high-risk inflammatory signature to monitor patients. In response to the increase of JAK-STAT pathway enrichment we treated two refractory CAR-TEC patients with Upadacitinib. Treatment with selective JAK1 inhibition was associated with reduced fecal calprotectin, decreased mucosal CD14 monocytes CAR-T infiltrate. Our patient had clinical improvement alongside near complete disappearance of circulating CAR-T in the PB.
Discussion
Our data establish that CAR-T induced enterocolitis is driven by an interferon dominated mucosal immune failure state arising from the intersection of deep B-cell depletion, stromal-endothelial breakdown, and persistent tissue infiltrating CAR-T cells. Our use of healthy controls and asymptomatic CAR-T controls highlights protective mucosal programs not evident from case-only studies and identifies practical biomarker and therapeutic hypotheses for risk stratification and mechanism-based intervention. Our study highlights the use of JAK1 inhibition as a viable and mechanistically justified treatment option to combat this severe adverse events.
DISCLOSURES
Adolfo Aleman, PhD: No relevant conflicts of interest to declare.